First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis

about

First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis

Item

http://www.wikidata.org/entity/Q57069646

description

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 25 September 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

First-line treatment strategie ...... kemia: a network meta-analysis

@en

First-line treatment strategie ...... kemia: a network meta-analysis

@nl

type

Item

label

First-line treatment strategie ...... kemia: a network meta-analysis

@en

First-line treatment strategie ...... kemia: a network meta-analysis

@nl

prefLabel

First-line treatment strategie ...... kemia: a network meta-analysis

@en

First-line treatment strategie ...... kemia: a network meta-analysis

@nl

P1476

First-line treatment strategie ...... kemia: a network meta-analysis

@en

P2093

Kang-Kang Chen

http://www.w3.org/2001/XMLSchema#string

Wei Yang

http://www.w3.org/2001/XMLSchema#string

P2860

The concept of treatment-free remission in chronic myeloid leukemia

Chronic myeloid leukemia: reminiscences and dreams

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Practical methods for incorporating summary time-to-event data into meta-analysis

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.

[Preliminary comparison of efficacy and safety of dasatinib and imatinib in newly diagnosed chronic myeloid leukemia].

An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.

P304

3891-3910

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CMAR.S177566

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kusheng Wu

Taifeng Du

P577

2018-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30288121

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

P932

6163008

http://www.w3.org/2001/XMLSchema#string